These include anesthetics [16], anti-amyloidogenics [17], antidiabetic [18,19], potent mineralocorticoid receptor antagonists [20], dual MDM2 and CDK4 inhibitors targeting glioblastoma [21], anti-cancer agents towards HCT-116 [22] and MCF-7 cancer cells [23]. This evidence concerns the gene NR3C2 and cancer.